Get to know KRTL, now available on Upstream under the ticker symbol ‘KRTL’
KRTL Holding Group, a diversified holding company focused on biotechnology innovation, global API sourcing, and cross-border distribution solutions, is now available on Upstream under the ticker symbol ‘KRTL’.
The dual listing on Upstream, part of MERJ Exchange, is designed to provide KRTL the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the company.
Details on the KRTL listing and deposit and trading instructions can be found at https://upstream.exchange/krtl. The Upstream market is open 7 days a week 20 hours a day, Monday to Sunday: 10:00am to 06:00am UTC+4 (1:00am to 9:00pm EST). Traders on Upstream’s smart-contract powered market will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations.
Note, U.S. or Canadian persons may not deposit, buy, or sell securities on Upstream.
Get to know KRTL Holding Group
For the Upstream community who may not know you yet, please give a short intro on who your company is?
KRTL Holding Group Inc. is a strategic holding company with operations through its subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. We focus on delivering regulatory consulting, pharmaceutical commercialization support, and cross-border infrastructure for biotech and agri-tech sectors. Our team specializes in navigating complex regulatory environments, including FDA, DEA, and 21 CFR compliance, while facilitating partnerships and licensing structures that enable U.S. market access and international distribution. With deep relationships in the U.S., South America, and Asia, KRTL is building a platform for trusted, scalable growth in emerging health and science-based markets.
What are one or two of your biggest initiatives this year as a company?
In 2025, KRTL continues to evolve its international production capabilities and scalable regulatory support services. Our FDA-anchored regulatory foundation, expanding Quality Management System (QMS), and growing pharmaceutical network allow us to offer high-value services such as:
What’s a recent trend in your industry that you believe sets up your company for success?
As global regulatory frameworks tighten and harmonize, there’s rising demand for trusted infrastructure that bridges international production with U.S. compliance standards. KRTL’s ability to provide an FDA-aligned platform — complete with strategic consulting, market entry support, and bilateral logistics — is directly aligned with this shift. We’re seeing increasing interest from early-stage pharmaceutical and nutraceutical companies seeking partners who can accelerate commercialization while navigating complex licensing and compliance issues across borders.
Why should shareholders be excited about the dual listing with Upstream?
The dual listing with Upstream offers KRTL increased visibility and accessibility in international capital markets, aligning perfectly with our mission of global reach. It enables investors from emerging and developed markets alike to engage with KRTL through a streamlined, blockchain-secured platform. This global presence supports our international partnerships and commercialization model, while offering the potential for improved liquidity and shareholder engagement through a forward-thinking, digital-first exchange.
Where can interested parties learn more about the dual listing?
Upstream profile page: https://upstream.exchange/krtl
Company website:
Have an issuer in mind that could benefit from reaching investors outside of the U.S.? Get started at https://upstream.exchange/GetListed. Traders can download Upstream from their preferred app store here: https://upstream.exchange/.
Disclaimers:
U.S. persons may not deposit, buy or sell securities on Upstream.
This communication does not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted.
Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company’s securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.
Forward-Looking Statements
This blog contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.